Media coverage about Arsanis (NASDAQ:ASNS) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arsanis earned a daily sentiment score of -0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.4019086324316 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several analysts have recently issued reports on ASNS shares. Citigroup downgraded Arsanis from a “buy” rating to a “neutral” rating in a research report on Monday, July 9th. Cowen downgraded Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. ValuEngine upgraded Arsanis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research downgraded Arsanis from a “buy” rating to a “hold” rating in a research report on Tuesday, May 15th. Finally, Cantor Fitzgerald set a $26.00 price objective on Arsanis and gave the company a “buy” rating in a research report on Thursday, May 10th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.00.
Shares of NASDAQ:ASNS traded down $0.01 on Friday, hitting $2.26. The company had a trading volume of 65,762 shares, compared to its average volume of 142,359. The company has a quick ratio of 7.38, a current ratio of 7.38 and a debt-to-equity ratio of 0.20. Arsanis has a 52-week low of $2.08 and a 52-week high of $28.69. The company has a market capitalization of $32.45 million and a P/E ratio of -0.14.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.